Scholar Rock (NASDAQ: SRRK) saw a substantial premarket stock increase of nearly 14% following the announcement of successful trial results. The company's experimental drug, apitegromab, when combined with Eli Lilly's tirzepatide, showed enhanced weight loss effects while maintaining significant lean body mass compared to tirzepatide usage alone. This promising development has captured the attention of investors and analysts alike.
https://www.gurufocus.com/news/2933404/scholar-rock-srrk-surges-after-promising-weight-loss-trial
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.